2-(2,6-二乙基苯基氨基)-2-咪唑烷 | 4751-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2,6-二乙基苯基氨基)-2-咪唑烷
• 英文名称: 2-(2,6-diethylphenylimino)imidazolidine
• 英文别名: (2,6-diethyl-phenyl)-(4,5-dihydro-1H-imidazol-2-yl)-amine；2,6-diethyl-N-(2-imidazolidinylidene)-benzamine；2-(2, 6-diethylphenyl-imino)-imidazolidine；2-(2,6-diethylphenyl-imino)-imidazolidine；N-(2,6-Diethylphenyl)-4,5-dihydro-1H-imidazol-2-amine
• CAS: 4751-48-8
• 化学式: C₁₃H₁₉N₃
• 分子量: 217.314
• InChiKey: IALHTUPVRAQZFI-UHFFFAOYSA-N

物化性质

• 熔点：
  61-63 °C
• 沸点：
  325.1±52.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2,6-二乙基苯基氨基)-2-咪唑烷 生成 N-(2,5-diethyl-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-amine
  参考文献：
  名称：

  YORK, B. M. ,, JR.

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-二乙基苯胺 在 水 、 三氯氧磷 作用下， 反应 6.0h， 生成 2-(2,6-二乙基苯基氨基)-2-咪唑烷
  参考文献：
  名称：

  A probe for octopamine receptors. Synthesis of 2-[(4-azido-2,6-diethylphenyl)imino]imidazolidine and its tritiated derivative, a potent reversible irreversible activator of octopamine-sensitive adenylate cyclase

  摘要：

  In order to develop an irreversible ligand for octopamine receptors, a highly potent azido-substituted 2-(phenyl-imino)imidazolidine (NC-5Z, 8) and its tritiated derivative (3H-NC-5Z, 11) have been designed and synthesized. Under reversible-binding conditions, NC-5Z is 50-100-fold more potent than octopamine in activating octopamine-sensitive adenylate cyclase in a variety of tissues. After photolysis, 3H-NC-5Z binds irreversibly to cell membranes, and this binding is reduced by preincubation with octopamine agonists and antagonists but not by norepinephrine, dopamine, serotonin, or histamine. NC-5Z should be useful both as a potent reversible octopamine agonist and as an affinity probe for characterizing and isolating octopamine-receptor proteins.

  DOI：

  10.1021/jm00128a022

文献信息

• Method for treating central nervous system disorders with substituted 2-imidazoline derivatives
  申请人：Hoener Marius

  公开号：US20070197569A1

  公开（公告）日：2007-08-23

  The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, X, A, and n are as defined in the specification and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms thereof.

  本发明涉及一种治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、如精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍、心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、X、A和n如规范中所定义，以及其药用活性盐、外消旋混合物、对映体、光学异构体和互变异构体形式。
• Propargyl-substituted 2-phenylamino-2-imidazolines and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US04025607A1

  公开（公告）日：1977-05-24

  Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, methyl, ethyl, methoxy or trifluoromethyl, and R.sub.4 and R.sub.5 are each hydrogen or propargyl, but other than both hydrogen or both propargyl at the same time, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as the salts are useful as analgesics and hypotensives.

  公式为##STR1##的化合物，其中R.sub.1、R.sub.2和R.sub.3可以相同也可以不同，分别为氢、氟、氯、溴、甲基、乙基、甲氧基或三氟甲基，R.sub.4和R.sub.5分别为氢或丙炔基，但不能同时为两个氢或两个丙炔基，以及其非毒性、药理学上可接受的酸盐；这些化合物及其盐可用作镇痛药和降压药。
• 2-(Trisubstituted phenylimino)-imidazolines
  申请人：Alcon Laboratories, Inc.

  公开号：US04461904A1

  公开（公告）日：1984-07-24

  2-Trisubstituted Phenylimino-imidazolines also known as 2-(trisubstituted anilino)-1,3 diazacyclopentene-(2) compounds and their use for lowering intraocular pressure are disclosed.

  2-三取代苯基亚胺咪唑啉，也被称为2-(三取代苯胺基)-1,3-二氮杂环戊烯-(2)化合物及其用于降低眼内压的用途被披露。
• Method for lowering intraocular pressure using phenylimino-imidazoles
  申请人：Alcon Laboratories, Inc.

  公开号：US04517199A1

  公开（公告）日：1985-05-14

  2-(Trisubstituted phenylimino)-imidazole compounds also known as 2-(trisubstituted anilino)-1,3 diazacyclopentene-(2) compounds are used to lower intraocular pressure.

  2-(三取代苯亚胺基)-咪唑化合物，也称为2-(三取代苯胺基)-1,3-二氮杂环戊烯-(2)化合物，用于降低眼内压。
• Method of lowering intraocular pressure using phenylimino-imidazoles
  申请人：——

  公开号：US04515800A1

  公开（公告）日：1985-05-07

  A method is provided of treating glaucoma in a patient which comprises administering, preferably as eye drops, an effective amount of the compound ##STR1## which is preferably in the form of its hydrochloride. The compound is administered preferably in the form of a sterile pharmacologically acceptable solution which contains from 0.1 to 5, and more preferably 0.1 to 2.0, percent by weight of said compound. The patient preferably obtains the anti-glaucoma agent in the form of a kit which comprises the sterile pharmacologically acceptable solution and an eyedropper for dispensing said sterile pharmacologically acceptable solution to the affected eyes of a patient suffering from glaucoma.

  提供了一种治疗青光眼的方法，包括向患者施用有效量的化合物##STR1##，最好是以眼药水的形式，该化合物最好是其盐酸盐形式。该化合物最好以含有0.1至5％，更好地为0.1至2.0％的所述化合物的重量百分比的无菌药理学可接受的溶液的形式施用。患者最好以一种套装的形式获得抗青光眼药剂，该套装包括无菌药理学可接受的溶液和一个眼滴瓶，用于向患有青光眼的患者的受影响的眼睛中注入所述无菌药理学可接受的溶液。